Opinion|Videos|November 21, 2025
Reinstating LDL-C Targets
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.
Episodes in this series
Panelists discuss how reinstating low-density lipoprotein cholesterol (LDL-C) targets could realign quality programs toward outcomes-driven care. Setting measurable goals encourages clinicians to intensify therapy and monitor progress.
They emphasize that outcomes-based incentives could harmonize payer and provider priorities, fostering accountability across systems. Restoring LDL-C targets may also reduce variability and close treatment gaps by making success measurable.
The discussion underscores that combining statin adherence metrics with LDL-C goal attainment could produce the most balanced and impactful framework.
Related to this article
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
Drug Price Drives Value of MASH Therapies More Than Efficacy
4
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
5